Q. Shi

发表

Blood-based tumour mutation index act as prognostic predictor for immunotherapy and chemotherapy in non-small cell lung cancer patients

Xueyan Zhang, Huimin Wang, H. Zhong, 2022, Biomarker research.

Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2

Zebo Huang, Y. Shu, Xin Zhou, 2015, Tumor Biology.

Hypoxia-induced Antizyme inhibitors 2 regulates cisplatin resistance through epithelia-mesenchymal transition pathway in non-small cell lung cancer.

L. Song, Ying Hu, Xinhui Huang, 2021, Pulmonary pharmacology & therapeutics.

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

B. Han, Xiaodong Zhao, Huimin Wang, 2019, Front. Oncol..

Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma

Jianxing He, Guangfa Wang, Junling Li, 2021, Theranostics.

Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first‐line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open‐label, parallel controlled clinical study

J Zhang, Jianxing He, Guangfa Wang, 2021, Cancer communications.

Ef ﬁ cacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study

He-long Zhang, Baolan Li, Yu-Mei Shi, 2022 .

MiR-181a inhibits non-small cell lung cancer cell proliferation by targeting CDK1.

Xiuxia Zheng, N. Ye, Qiaolin Chen, 2017, Cancer biomarkers : section A of Disease markers.

Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression

K. Shen, Jiayi Wu, Deyue Liu, 2023, BMC Cancer.

Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Hua Zhang, Yueping Shen, Maomin Sun, 2011, Pathology, research and practice.

Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals

Huimin Wang, H. Zhong, Jun Lu, 2022, Frontiers in Cell and Developmental Biology.

1445P CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study

J. Yang, Junpei Wang, Baorui Liu, 2020 .